Pharmacokinetics of Fluvastatin in Subjects with Renal Impairment and Nephrotic Syndrome-Reference-Cited by-同舟云学术

Pharmacokinetics of Fluvastatin in Subjects with Renal Impairment and Nephrotic Syndrome

Published:2002-03 Issue:3 Volume:42 Page:312-318
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Appel-Dingemanse S.,Smith T.,Merz M.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference39 articles.

1. HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia;Kathawala;Med Res Rev,1991

2. Basic prescribing information Lescol® (fluvastatin sodium) gelatine capsules, 20 mg and 40 mg, and Lescol®XL (fluvastatin sodium) prolonged-release tablets, 80 mg October 2000

3. Fluvastatin: a review of its use in lipid disorders;Langtry;Drugs,1999

4. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the fluvastatin angiographic restenosis (FLARE) trial;Serruys;Eur Heart J,1999

5. The effect of fluvastatin on coronary artery disease during one year of treatment;Riegger;Atherosclerosis,1999

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Renal Impairment Influence on Metabolic Drug Clearance using a Modelling Approach;Clinical Pharmacokinetics;2023-01-11

3. Clearance of cardiovascular medications during hemodialysis;Current Opinion in Nephrology and Hypertension;2016-05

4. KDOQI US Commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD;American Journal of Kidney Diseases;2015-03

5. The use of fluvastatin in cardiovascular risk management;Expert Opinion on Pharmacotherapy;2008-05-12